Kronos Bio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference
Kronos Bio, Inc. (Nasdaq: KRON) announced participation in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7 a.m. ET. The event will be webcast live and archived on the company's website for one month. Kronos Bio specializes in therapies aimed at cancer treatment, particularly through their investigational therapies like entospletinib for NPM1-mutated acute myeloid leukemia and KB-0742 for MYC-amplified solid tumors.
- Participation in a prominent investment conference can enhance visibility among investors.
- Webcast of the event allows for broad investor access and engagement.
- Focus on innovative cancer therapies may attract investment interest.
- None.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13th at 7 a.m. ET.
The fireside chat will be webcast live from the Investors & Media section of the company’s website at www.kronosbio.com. A replay of the webcast will be archived and available for one month following the event.
About Kronos Bio, Inc.
Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio’s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.
Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.
Investors:
Claudia Styslinger
Argot Partners
212-600-1902
kronosbio@argotpartners.com
Media:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com
FAQ
When will Kronos Bio participate in the H.C. Wainwright Conference?
Where can I watch the Kronos Bio fireside chat?
What is the main focus of Kronos Bio's research?
What therapies is Kronos Bio currently developing?
